Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Interaction Study of Milvexian and Atorvastatin in Healthy Participants
NCT04388501Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milvexian in thromboembolism (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-time Curve. Started Jun 2021; status: completed.
02
Drugs
milvexian
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04388501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388501.